My name is Elianne Bulthuis, I am Dutch, PhD candidate at the Department of Biochemistry, theme Mitochondrial diseases
When you were a kid what did you want to be when you grew up? Can you tell us something about your child years.
As a kid, I really wanted to become a physician, either a surgeon or gyneacologist. My favorite game was to “play doctor”’, my grandpa being my favorite patient.
What was your previous academic training, where did you study and why that study?
At some point, that idea of becoming a physician started to scare me a little bit. I was still highly interested in medical subjects, but the biology curriculum appealed more to me than biomedical sciences did. That’s why I decided to study Biology and specialize in Biomolecular sciences, both at the Vrije Universiteit in Amsterdam.
The RIMLS motto is: ‘Today’s molecules for tomorrow’s medicine’. What does this mean for you?
My project is quite fundamental, so the motto does not directly apply to my research. However, understanding the bidirectional links between mitochondrial structure and function is essential in the search for a cure to mitochondrial diseases. So hopefully, my work can contribute to “tomorrow’s medicine”!
Who is your great example as scientists? And please give a motivation why.
I don’t really have a specific example. So many people did amazing work in the past, providing a strong base for research nowadays.
Which research discovery that you have made has made you most proud?
I guess such a discovery is yet to come!
Given unlimited finance what experiment would you perform?
I would apply lots of microscopic techniques to many (mitochondrial patient) cell lines treated with many compounds to see which can restore mitochondrial structure and function.
What does your working area (desk, office) look like and what does it say about you (or your research)?
It is kind of an organized chaos, not too tidy but I always know where to find things. I am not sure what this says about me, since I can be a bit chaotic (or probably simply too busy), but I am usually quite organized when I do experiments.
Nominate a colleague to be in the spotlight and what would you like to ask him or her?
I would like to nominate Bodine Bezemer. We did our master’s together in Amsterdam, and I think it is really nice that our paths cross again here in Nijmegen!
What type of person are you, quick insights:a) Mac or PC? : PC
b) Theater or cinema? : Theater
c) Dine out or dine in? : Dine out
d) Ferrari or Fiat? : Fiat
e) Shopaholic or chocoholic? : Difficult to choose, probably chocoholic?
f) Culture or Nature : Impossible to make a choice!
Related news items
4,8 million euros for prevention of tuberculosis among people with diabetes in Africa16 July 2019
Reinout van Crevel and Lindsey te Brake have received European funding of 4.8 million euros to lead an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB.read more
Handbook of biomarkers and precision medicine a new publication by Alain van Gool12 July 2019
Alain van Gool published a new handbook on biomarkers and applications in (pre)clinical drug development for precision medicine.read more
Successful Summer School by CMBI, TML and Human Genetics8 July 2019
CMBI, TML and Human Genetics organized a successful Summer School on 'Integrative X-omics Analyses Empowering Personalized Healthcare'.read more
Summer greetings from René Bindels5 July 2019
In this last newsletter before the summer break and before I wish you all a happy holiday, I would like to briefly summarize the first half of 2019 and especially look ahead to the interesting activities that will take place in the second half of the year.read more
Prostate cancer theranostics imaging, surgical guidance, and targeted photodynamic therapy5 July 2019
In Theranostics, Mark Rijpkema and colleagues present the development of a novel multimodal tracer that targets both preoperative imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing prostate cancer.read more